drugset / Trial / NCT03792087

Efficacy and Safety of SmofKabiven Peripheral Versus Compounded Emulsion

NCT03792087 ↗

Phase 3 Completed 272 enrolled Fresenius Kabi Parexel · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The present protocol describes a randomized, open-labelled study in which either SmofKabiven Peripheral or a hospital compounded control Parenteral Nutrition (PN) regimen will be given to adult surgical patients for 5 consecutive days. As serum prealbumin is a well-established surrogate efficacy parameter reflecting the patient´s nutritional status, the absolute change of the serum prealbumin level at the day of the final study visit compared to baseline will represent the primary efficacy parameter in the present study.

Timeline

Start
2017-12-21
Primary completion
2018-12-30
Completion
2018-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject SmofKabiven Peripheral Unknown 34.3 unknown Intravenous

Indications

No indication recorded.